Specialty chemicals company Evonik has kicked off a major expansion project at two German facilities, aimed at serving the European market for active pharmaceutical ingredients (APIs) and advanced intermediates.
The first stage of the project is a 25 million-euro ($27 million) investment, due to be completed by the middle of 2021. The entire project is expected to be finalized before 2024.
As well as increasing production capacity for APIs and advanced intermediates within Europe, two multi-purpose cGMP sites in Dossenheim and Hanau will be expanded.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze